CRNX Company Profile and Key Details

Q: Who are the executives of CRNX?

Ms. Adriana Cabre M.B.A.Chief HR OfficerMr. Kevin CappsHead of Intellectual PropertyMr. James HassardChief Commercial OfficerMr. Jeff E. KnightChief Operating OfficerMr. Chris Robillard M.B.A.Chief Bus. OfficerMr. Marc J. C. WilsonChief Financial OfficerDr. Alan S. Krasner M.D.Chief Medical OfficerDr. R. Scott Struthers Ph.D.Founder, Pres, Chief Executive Officer & DirectorDr. Dana Pizzuti M.D.Chief Devel. OfficerDr. Stephen F. Betz Ph.D.Founder & Chief Scientific OfficerMs. Garlan AdamsGen. Counsel & Corporation Sec.

NASDAQ : CRNX

Crinetics Pharmaceuticals

$83.49

-0.04-0.05%

At Close 4:00 PM

66.51

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Price Chart

Stock Price Today

Crinetics Pharmaceuticals, Inc. (CRNX) stock declined over -0.05%, trading at $83.49 on NASDAQ, down from the previous close of $83.53. The stock opened at $83.55, fluctuating between $83.44 and $83.57 in the recent session.

Stock Snapshot

83.53

Prev. Close

8.8B

Market Cap

83.44

Day Low

-16.27

P/E Ratio

-5.13

EPS (TTM)

-2.55

Cash Flow per Share

83.55

Open

105.44M

Number of Shares

83.57

Day High

92.51%

Free Float in %

8.03

Book Value

17.89M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 08, 2026	83.52	83.57	83.44	83.49	17.89M
Jul 07, 2026	83.58	83.63	83.43	83.53	80.72M
Jul 06, 2026	42.03	44.11	41.39	42.03	4.87M
Jul 02, 2026	40.00	42.42	39.83	42.23	2.18M
Jul 01, 2026	37.49	39.43	37.37	38.68	1.17M
Jun 30, 2026	37.11	37.90	36.68	37.42	748.86K
Jun 29, 2026	36.39	37.31	35.74	36.94	873.77K
Jun 26, 2026	35.52	36.91	35.11	36.70	5.05M
Jun 25, 2026	35.88	36.66	34.71	34.99	1.45M
Jun 24, 2026	36.40	37.67	36.01	36.18	1.74M
Jun 23, 2026	35.47	36.68	35.44	35.91	934.98K
Jun 22, 2026	35.91	37.07	35.28	35.38	962.79K
Jun 18, 2026	36.34	36.79	35.05	35.87	2.01M
Jun 17, 2026	35.00	36.40	34.79	35.75	743.64K
Jun 16, 2026	35.26	35.50	34.26	35.00	688.53K
Jun 15, 2026	34.58	36.16	34.38	35.12	931.25K
Jun 12, 2026	33.53	35.10	33.40	34.47	1.04M
Jun 11, 2026	34.40	34.48	32.71	33.53	1.76M
Jun 10, 2026	34.32	35.89	33.85	34.32	625.28K
Jun 09, 2026	33.77	35.09	33.54	34.97	884.52K

Contact Details

San Diego, CA 92121

United States

https://www.crinetics.com 858 450 6464

About Company

Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.

Stock Peers

ARGX

-4.64-0.50%

argenx SE$915.30 REGN

-13.35-1.97%

Regeneron Pharmaceuticals, Inc.$662.88 MDGL

20.04+3.67%

Madrigal Pharmaceuticals, Inc.$565.40 UTHR

-9.36-1.66%

United Therapeutics Corporation$554.34 VRTX

-23.82-4.56%

Vertex Pharmaceuticals Incorporated$498.43 KRYS

6.8+1.84%

Krystal Biotech, Inc.$375.40 PRAX

9.04+2.79%

Praxis Precision Medicines, Inc.$332.99 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

1.91+0.59%

Alnylam Pharmaceuticals, Inc.$323.50 LGND

-4.55-1.42%

Ligand Pharmaceuticals Incorporated$314.88

Company Overview

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) closed at $83.49 USD, losing -$0.04 (-0.05%) from the previous close of $83.53. The stock is currently trading near its 52-week high $25.83 and $83.63. With a market capitalization of about $8.80 billion, Crinetics Pharmaceuticals, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.23). Key stats such as the average daily volume over the past year has been around 2.85 million shares, trading with heavier-than-usual volume. Headquartered in San Diego, CA, Crinetics Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO R. Scott Struthers, the company employs approximately 594 people and listed since July 18, 2018. Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 -4.57%, SMA50 -10.58%, SMA200 11.83%). The stock’s 14-day RSI is 39.15 (weak momentum), while the ATR of 2.22 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -24.57% below its high and over 81.49% above its low. Average 10-day trading volume of 15.49 million shares is significantly above the 3-month average of 2.95 million, indicating heightened recent market interest.

Valuation Metrics

Crinetics Pharmaceuticals, Inc. trades at a P/E ratio of -16.24, slightly below the S&P 500 average, with a price-to-sales ratio of 487.2 and a price-to-book ratio of 6.79 trading at moderately above to book value. The P/FCF stands at -20.98, also above market averages.

Dividend & Fair Value

Crinetics Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$11.58. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Crinetics Pharmaceuticals, Inc. generated EPS of -$4.53 over the past year. Five-year average earnings growth is -12.11%. Wall Street analysts project EPS growth of -0.67% annually over the next five years. The latest quarter delivered EPS of -$1.23. The next quarter is forecast at -$1.35. Next year's EPS is expected at $4.77. Analyst sentiment is bullish. Analyst rating data shows there are 17 Strong Buy ratings, 3 Buy ratings, 4 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $143.00 to $40.00. The high target offers 71.28% upside. The low target suggests -52.09% downside. The mean target is $84.92. This offers 1.71% upside. Crinetics Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended May 07, 2026, missed forecasts by 0.82%. The prior quarter beat by -5.84%. Over the last six quarters, Apple has recorded several small beats. These include -4.35% in February 27, 2025.

Shareholding & Insider Activity

Crinetics Pharmaceuticals, Inc. has 94.18 million shares outstanding. The public float is 92.78 million shares, elevated short interest at 16.79% of float. This equals 13.90 million shares. The short ratio is 14.63 days. Institutional investors hold 116.75% of the float. Insiders own 2.01%. EDELMAN JOSEPH holds 5.32 million shares, PERCEPTIVE ADVISORS LLC has 5.32 million shares and 5AM Ventures IV, L.P. has 2.27 million shares. Over the past six months, insider transactions show net selling. They sold 115.99 thousand shares across 9 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Crinetics Pharmaceuticals generated $4.01M in revenue, or $0.07 per share. Gross margin was 72.64%, operating margin -5547.17%, and net profit margin -5345.85%. Returns are negative, with ROA at -33.77% and ROE at -39.79%.
On valuation metrics, Crinetics Pharmaceuticals trades at a P/E of -16.24, P/S of 487.20 and P/B of 6.79. The current ratio is 18.60 and quick ratio is 18.56. Operationally, the company’s inventory turnover is 0.07 and cash conversion cycle is -17797.58 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.04, supported by a cash flow-to-debt ratio of -8.65.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Crinetics Pharmaceuticals posted revenue of $4.01M, down slightly from $4.74M in the prior quarter. Gross profit was $2.92M (margin 72.64%). Operating income was - $222.61M (margin -5547.2%). Net income was- $214.53M (EPS - $3.69).
The company ended the quarter with $558.56M in cash and short-term investments, a total debt of $51.73M, and net debt of - $3.17M. Total assets were $635.35M, with equity of $539.11M. Financials further reflected weakness, with operating cash flow of - $166.31M, free cash flow of - $171.00M, and capital expenditures of - $4.69M.

Price Forecast & Outlook

Our AI price prediction model suggests that Crinetics Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 9.55%, with price expected at $91.46 by July 22, 2026, within a range of $89.78 to $93.12 3-Month Outlook: Projected rise of 3.01%, reaching $86.00 by October 06, 2026, with a range of $82.25 to $89.62. 1-Year Outlook: Projected gain of 5.88%, with price at $88.40 by July 08, 2027, within a range of $84.67 to $92.18.

Key Takeaways

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) shares are up 19.63% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Crinetics Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -16.24. Analyst sentiment is cautious, with the majority of ratings in In-Line territory and a mean price target of $66.32, suggesting -20.57% downside. Our AI forecast model points to short-term strength (9.55% over two weeks), a medium-term rise (3.01% over three months), and a longer-term gain (5.88% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Crinetics Pharmaceuticals, Inc. (CRNX) stock price?

Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) stock price is $83.49 in the last trading session. During the trading session, CRNX stock reached the peak price of $83.57 while $83.44 was the lowest point it dropped to. The percentage change in CRNX stock occurred in the recent session was -0.05% while the dollar amount for the price change in CRNX stock was - $0.04.

CRNX's industry and sector of operation?

The NASDAQ listed CRNX is part of Biotechnology industry that operates in the broader Healthcare sector. Crinetics Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CRNX?

Ms. Adriana Cabre M.B.A.
Chief HR Officer
Mr. Kevin Capps
Head of Intellectual Property
Mr. James Hassard
Chief Commercial Officer
Mr. Jeff E. Knight
Chief Operating Officer
Mr. Chris Robillard M.B.A.
Chief Bus. Officer
Mr. Marc J. C. Wilson
Chief Financial Officer
Dr. Alan S. Krasner M.D.
Chief Medical Officer
Dr. R. Scott Struthers Ph.D.
Founder, Pres, Chief Executive Officer & Director
Dr. Dana Pizzuti M.D.
Chief Devel. Officer
Dr. Stephen F. Betz Ph.D.
Founder & Chief Scientific Officer
Ms. Garlan Adams
Gen. Counsel & Corporation Sec.

How CRNX did perform over past 52-week?

CRNX's closing price is 223.23% higher than its 52-week low of $25.83 where as its distance from 52-week high of $83.63 is -0.17%.

How many employees does CRNX have?

Number of CRNX employees currently stands at 437.

Link for CRNX official website?

Official Website of CRNX is: https://www.crinetics.com

How do I contact CRNX?

CRNX could be contacted at phone 858 450 6464 and can also be accessed through its website. CRNX operates from Building No. 2, San Diego, CA 92121, United States.

How many shares of CRNX are traded daily?

CRNX stock volume for the day was 17.89M shares. The average number of CRNX shares traded daily for last 3 months was 2.85M.

What is the market cap of CRNX currently?

The market value of CRNX currently stands at $8.80B with its latest stock price at $83.49 and 105.44M of its shares outstanding.

Employees	437
Beta	0.23
Sales or Revenue	$4.01M
5Y Sales Change%	-0.654%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

CRNX Company Profile and Key Details

Crinetics Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Company Overview

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Technical Performance

Shareholding & Insider Activity

Earnings & Analyst Outlook

Valuation Metrics

Key Takeaways

Price Forecast & Outlook